CardiaMetrics Raises $1.76M for Cardiac Monitoring Device

CardiaMetrics, a company specializing in implantable medical devices for cardiac function assessment, has secured $1,759,924 in investment capital. This funding round marks a pivotal step for the company, which was established in December 2023 and operates from bases in Caen and Grenoble. The investment will accelerate CardiaMetrics' mission to market innovative solutions for patient home monitoring. The company's core offering stems from six years of extensive research and development into an implantable medical device designed to assess cardiac function. CardiaMetrics aims to provide effective home monitoring for patients with serious illnesses, such as cancer or heart failure, who require long-term follow-up. A key focus is to ensure patient adherence by minimizing the mental burden associated with their pathology, achieved through a system that does not depend on continuous patient actions. Furthermore, CardiaMetrics is developing technology that provides medical teams with critical intracardiac pressure variation data. This biomarker is presented as reliable, actionable, and predictive, enabling more precise therapeutic adjustments and personalized patient care. The newly secured capital is designated to advance the ongoing development of this medical device and to support the strategic initiatives required for its market entry. Looking ahead, CardiaMetrics plans to deploy its solution across North America and Europe. This expansion strategy includes conducting clinical investigations between 2025 and 2027, with the ultimate goal of obtaining FDA approval and CE certification in 2028. The company’s growth trajectory is focused on bringing its innovative home monitoring technology to patients and healthcare providers globally.